Who are PF-02341066's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): X-396 (ensartinib), Crizotinib Capsules.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pf-02341066.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

PF-02341066 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PF-02341066 (PF-02341066) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ALK/ROS1 tyrosine kinase inhibitor. Area: Oncology.

phase 3 ALK/ROS1 tyrosine kinase inhibitor ALK, ROS1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

PF-02341066 (PF-02341066) — Pfizer. PF-02341066 is a tyrosine kinase inhibitor that targets ALK (anaplastic lymphoma kinase) and ROS1 to block aberrant signaling in cancer cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
PF-02341066 TARGET	PF-02341066	Pfizer	phase 3	ALK/ROS1 tyrosine kinase inhibitor	ALK, ROS1
X-396 (ensartinib)	X-396 (ensartinib)	Xcovery Holdings, Inc.	phase 3	ALK and ROS1 kinase inhibitor	ALK, ROS1
Crizotinib Capsules	Crizotinib Capsules	Shouyao Holdings (Beijing) Co. LTD	phase 3	ALK/ROS1 tyrosine kinase inhibitor	ALK, ROS1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ALK/ROS1 tyrosine kinase inhibitor class)

Pfizer · 1 drug in this class
Shouyao Holdings (Beijing) Co. LTD · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PF-02341066 — Competitive Intelligence Brief. https://druglandscape.com/ci/pf-02341066. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing